GlassScriptPhysician profile
Mario D Lacerna
NPI 1326130725
$3,114.41
in general payments reported to CMS, 2019-2025
20 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.68 · 2020: $375 · 2021: $625 · 2022: $721 · 2023: $641 · 2024: $406 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $375.00 | 2020-2021 | |
| Janssen Biotech, INC. | $375.00 | 2022-2024 | Erleada, Akeega |
| Siemens Medical Solutions USA, INC. | $345.55 | 2023-2025 | |
| Genzyme Corporation | $250.00 | 2021 | |
| Seagen INC. | $250.00 | 2021-2022 | |
| Reflexion Medical, INC. | $156.00 | 2024 | Reflexion Medical Radiotherapy System |
| Blueprint Medicines Corporation | $134.82 | 2023 | Ayvakit |
| Genentech USA, INC. | $125.00 | 2022 | |
| Lilly USA, LLC | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Opdivo |
| Amgen INC. | $125.00 | 2022 | |
| Epizyme, INC. | $125.00 | 2021 | |
| Pfizer INC. | $125.00 | 2024 | |
| Eisai INC. | $124.55 | 2020 | |
| Tempus Ai, INC | $107.13 | 2025 | Xt Cdx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $96.15 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $71.12 | 2023 | Imfinzi |
| Merz North America, INC. | $39.68 | 2019 | |
| Progenics Pharmaceuticals, INC. | $25.71 | 2025 | |
| Icad, INC | $13.70 | 2023 | Axxent Surface Controller |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Lacerna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.